MIM
VRCA icon

MetLife Investment Management’s Verrica Pharmaceuticals VRCA Stock Holding History

MetLife Investment Management’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,189
Closed -$86.7K – 2896
2024
Q2 		$86.7K Buy
+1,189
New +$91.3K ﹤0.01% 2664
2023
Q3 		– Sell
-1,119
Closed -$64.6K – 2986
2023
Q2 		$64.6K Buy
+1,119
New +$67.9K ﹤0.01% 2870

Other funds holding VRCA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

MetLife Investment Management's VRCA Position: Q3 2024 in Review

MetLife Investment Management sold out of Verrica Pharmaceuticals (VRCA) in Q3 2024, closing a stake of 1,189 shares — an estimated $86.7K sold.

MetLife Investment Management first reported a position in VRCA in Q2 2023 and held it in 2 quarters. The position peaked at $86.7K in Q2 2024. 79 funds tracked by Wall St. Rank hold VRCA as of Q3 2024.

  • MetLife Investment Management reported no remaining Verrica Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • MetLife Investment Management sold 1,189 Verrica Pharmaceuticals shares in Q3 2024, an estimated $86.7K.
  • MetLife Investment Management first reported a position in Verrica Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • MetLife Investment Management's Verrica Pharmaceuticals position peaked at $86.7K in Q2 2024.
  • 79 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2024.

Based on MetLife Investment Management's 13F filing for Q3 2024, filed 13 Nov 2024.